InnoCan Pharma's CBD Delivery Platform Achieves 28-Day Sustained Release in Regulatory Study
核心洞察
InnoCan Pharma (搜索)'s liposomal platform technology demonstrated sustained CBD plasma concentrations for 28 days following a single subcutaneous injection in a peer-reviewed study published in Precision Nanomedicine.
The research conducted in Göttingen minipigs showed favorable safety profiles with no systemic adverse effects and metabolic pathways consistent with human responses.
The company has secured FDA alignment on its preclinical development strategy and is preparing for an Investigational New Drug application to advance toward human clinical trials.
InnoCan Pharma (搜索) has achieved a significant milestone with the publication of pivotal research validating its proprietary liposomal platform technology (LPT) for sustained drug delivery. The peer-reviewed study, published in Precision Nanomedicine, demonstrates that a single subcutaneous injection can maintain therapeutic CBD plasma concentrations for an extended 28-day period, representing a potential breakthrough in sustained drug delivery systems.
Breakthrough Research Validates Extended Release Profile
The research was conducted using Göttingen minipigs, a regulatory-recognized animal model known for accurately predicting human metabolic responses. This experimental design evaluated both pharmacokinetic performance and crucial safety parameters, addressing key requirements for pharmaceutical development.
Key findings from the study include sustained drug release with detectable CBD concentrations persisting throughout the entire 28-day observation period following a single administration. The research also revealed human applicability, as elevated blood levels of the metabolite 7-COOH-CBD indicate metabolic pathways consistent with expected human responses.
The safety profile proved favorable, with no systemic adverse effects reported and good local tolerance observed at injection sites throughout the study duration. This independent verification of InnoCan's drug delivery platform represents what industry observers term a "de-risking event" that could build market confidence in the technology.
FDA Alignment Provides Regulatory Clarity
Beyond the scientific validation, InnoCan has secured additional momentum through confirmed alignment with the U.S. Food and Drug Administration (搜索) regarding its preclinical development strategy. This regulatory clarity removes uncertainties commonly associated with novel drug delivery technologies and establishes a defined framework for transitioning to human clinical trials.
The successful toxicity study represents the completion of essential testing required before entering the formal FDA approval process. The company now has an established framework for progression toward human trials, with the minipig data forming the foundation for an Investigational New Drug (IND) application necessary to commence human clinical trials.
Market Positioning for Chronic Pain Management
The 28-day sustained release profile strategically positions InnoCan in the pain management market, where current standards often require daily oral medications or frequent injections. This technology could effectively address patient compliance challenges while offering a non-opioid alternative for chronic pain (搜索) management.
The sustained-release capability could transform chronic pain (搜索) management approaches, as InnoCan's platform technology is capable of delivering steady CBD release for extended periods from a single injection, positioning LPT-CBD as a potentially disruptive non-opioid alternative.
Capital Market Strategy Accelerates
With scientific validation achieved, focus now shifts to commercialization efforts. The company is accelerating its capital market strategy, confirming participation in the ThinkEquity (搜索) Conference 2025, signaling coordinated initiatives to increase visibility among U.S. institutional investors.
Reports confirm the company is collaborating with New York-based investment bank ThinkEquity (搜索) to prepare for a potential Initial Public Offering in the United States. This strategic initiative is aimed at raising fresh capital, as the forthcoming registration studies represent a significant financial undertaking, and a US listing could provide the necessary liquidity to fund them.
The combination of peer-reviewed scientific validation and regulatory alignment creates a favorable environment for advancing through subsequent development phases, as the company transitions from preclinical research to clinical development.